REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today that Clalit Health Services, Israel’s largest and the world’s second largest health maintenance organization (HMO), has established a reimbursement coverage policy for Rosetta Genomics’ miRview™ mets test. Initially, reimbursement will be provided to patients participating in a clinical study being conducted at three medical centers in Israel, with plans to expand reimbursement for the test to all Clalit members.
